Celocurine (succinylcholine) is administered in specific clinical settings to provide skeletal muscle relaxation. It is commonly utilized to facilitate procedures that require muscle control for brief periods, such as the initial placement of a breathing tube (endotracheal intubation) necessary for establishing an airway during general anesthesia. The medication may also be employed during procedures like electroconvulsive therapy (ECT) to help manage strong muscle activity.

The primary therapeutic purpose of Celocurine is to help healthcare professionals safely manage a patient's muscles during these critical, short-duration interventions. The overall benefit is facilitating controlled, necessary medical procedures. For a comprehensive overview of the approved indications and detailed clinical scenarios for use, patients and caregivers should refer to the official product information.

---

Quick Fact: Relief for procedural muscle tension

---

Official Eligibility and Contraindications

The eligibility for Celocurine (Succinylcholine Chloride) is strictly defined by regulatory documents, primarily to mitigate the risk of severe hyperkalemia and malignant hyperthermia.

---

Contraindicated Populations (Must Not Use)

• Individuals with a personal or familial history of Malignant Hyperthermia (MH).
• Patients with Skeletal Muscle Myopathies or Congenital Myotonic Diseases.
• Patients in the acute phase of injury following major burns, multiple trauma, or extensive denervation of skeletal muscle.
• Patients with known hypersensitivity to the drug or pre-existing, significant hyperkalemia.

---

Age-Group and Condition Restrictions

• Pediatric Patients: Use is restricted and generally reserved for emergency intubation due to the risk of hyperkalemic rhabdomyolysis in children with undiagnosed myopathy. Routine or elective use is not recommended.
• Organ Impairment: Use requires caution in patients with severe hepatic disease or renal impairment, as reduced plasma cholinesterase may cause a prolonged blockade.
• Pregnancy/Lactation: The label advises caution for use during pregnancy, noting that reduced cholinesterase levels may prolong the drug's effect. Caution is recommended in nursing mothers as excretion into human milk is unknown.

The interaction profile of Celocurine (Suxamethonium Chloride) is strictly defined by specific pharmacokinetic and pharmacodynamic relationships documented in regulatory sources.

A significant pharmacokinetic interaction involves co-administration with substances that reduce the activity of plasma cholinesterase, the primary enzyme for Celocurine’s clearance. Agents like acetylcholinesterase inhibitors can reduce metabolism, resulting in prolonged neuromuscular blockade. This effect is also a consideration for individuals with a known genetic variation of the cholinesterase enzyme.

Pharmacodynamic potentiation is documented with numerous medicinal products, including aminoglycoside antibiotics, antiarrhythmics (such as quinidine and lidocaine), lithium salts, and magnesium salts, all of which can enhance the muscle-relaxing effect. Due to the risk of Celocurine inducing hyperkalemia, it must be used with great caution in patients receiving cardiac glycosides (e.g., digitalis) because of the documented potential for serious cardiac arrhythmias.

An administration-based restriction requires that Celocurine must not be mixed in the same syringe with alkaline solutions like barbiturates due to chemical incompatibility. Furthermore, official warnings note that the combination of Celocurine with volatile anesthetic agents increases the risk of Malignant Hyperthermia in susceptible individuals.

Mechanism of Action: Neuromuscular Depolarizing Blockade

Celocurine (Suxamethonium Chloride) exerts its effect through a highly localized, peripheral intervention at the neuromuscular junction (NMJ). As a high-potency agonist, the molecule binds to and persistently activates the Nicotinic Acetylcholine Receptors (nAChRs) on the skeletal muscle motor endplate . This action initiates a massive, continuous influx of cations, forcing the muscle cell membrane into a state of sustained depolarization.

This continuous electrical state prevents the cell from repolarizing and resetting, rendering adjacent voltage-gated sodium channels refractory. The subsequent inability of the muscle fiber to propagate a new action potential results in a complete, flaccid skeletal muscle paralysis. The termination of this block is dictated by its rapid systemic clearance: the drug is quickly broken down in the plasma by the enzyme plasma cholinesterase. The hydrolysis of Suxamethonium rapidly lowers its concentration below the blocking threshold, allowing the muscle membrane to spontaneously repolarize and regain excitability.

How Celocurine is Used

Celocurine (suxamethonium chloride) is an ultra-short-acting neuromuscular-blocking agent administered exclusively in controlled clinical environments. Its administration is strictly governed by specialized protocols.

---

Official Administration Routes and Schedules

This medicine is supplied as a sterile solution for injection and is administered via the Intravenous (IV) route for its primary use. The Intramuscular (IM) route is reserved only for situations where IV access is not immediately feasible.

The dosage is highly individualized and is determined by patient weight and clinical need. For short procedures such as endotracheal intubation, a single IV bolus injection is typically used, with an average dose of 0.6 mg/kg body weight (range of 0.3 mg/kg to 1.1 mg/kg). Due to the drug’s ultra-short duration of effect, this single IV dose typically lasts only 4 to 6 minutes.

For longer procedures, muscle relaxation is maintained either by administering subsequent, smaller intermittent IV injections (e.g., 0.04 mg/kg to 0.07 mg/kg) or through a continuous IV infusion, which is generally maintained at a rate of 2.5 mg/minute to 4.3 mg/minute in adults.

---

Preparation and Contextual Requirements

Administration must only be performed by personnel skilled in artificial respiration and when equipment for tracheal intubation and ventilation is instantly available. Prior to its use, unconsciousness must be induced via general anesthesia to prevent patient distress.

If continuous infusion is required, the solution must be diluted to a concentration of 1 mg/mL or 2 mg/mL. The solution is acidic and must not be mixed with alkaline solutions (such as thiopental) to prevent precipitation.

Research evidence / Overview of studies for Celocurine

---

Evidence for Use in Facilitating Endotracheal Intubation

This section will summarize the structure of research, primarily Randomized Controlled Trials (RCTs) and Systematic Reviews, which have studied Celocurine's effects on immediate muscle relaxation during the placement of a breathing tube.

Research into Celocurine's primary use in anesthesia has explored how quickly and reliably the medicine is associated with profound muscle relaxation when used to allow for endotracheal intubation—the placement of a tube to manage a patient’s airway. The outcomes monitored by researchers focus heavily on measurements of speed and timing, such as the time from injection until maximal muscle relaxation is achieved, the quality of conditions for placing the tube (e.g., jaw position and vocal cord movement), and whether the drug was evaluated against other agents.

Findings described in many trials and systematic reviews report patterns of rapid onset and short duration of muscle relaxation. Studies report that patients observed in these trials had recovery of spontaneous muscle function within a brief timeframe, typically just a few minutes. However, some large analyses involving many different trials described mixed findings or statistical variability across studies when comparing Celocurine's action to other agents, indicating that results can vary depending on the specific trial conditions.

---

Evidence for Use in Specialized Short Medical Procedures

This area will outline the types of research and clinical documentation that have examined Celocurine's use in providing brief, controlled muscle relaxation for short, time-critical medical interventions like Electroconvulsive Therapy (ECT) and other specialized procedures.

For procedures that require profound, temporary muscle stillness but last only a short time, Celocurine was observed in various clinical settings. This includes research exploring its association with muscle activity patterns during Electroconvulsive Therapy (ECT). Studies have explored how the medicine's time of action is measured in the context of procedural timing.

What remains uncertain is that the evidence base for these specialized uses includes data derived from observational settings and historical clinical reports, rather than exclusively from modern, placebo-controlled trials. For the use in ECT, research is usually directed toward measuring the medicine's effects and recovery profile, rather than comparing it against non-use, which is an uncommon study design in this specialized area.

---

Long-Term Evidence and Observation Durations

There is limited information for long-term outcomes, as studies focus primarily on the immediate success and recovery from the procedure itself. The research that supports Celocurine's primary use focuses on ultra-short-term outcomes because the medicine’s effects are intended to last only a few minutes. Therefore, the vast majority of studies monitor patient response and recovery only for the immediate period surrounding the procedure.

---

Evidence in Specific Patient Populations

Celocurine was evaluated in studies involving pediatric patients, where research explored its use in emergency and critical care settings that require rapid airway management. These studies focus on measuring the effect of different dose levels observed in adult populations.

Research also explores the effects of Celocurine in people who have genetic variations that affect the enzyme responsible for breaking down the medicine in the body. Studies have observed that in certain individuals, this variation was associated with a prolonged duration of muscle relaxation. Findings from these specialized observational studies and reports help contextualize patterns observed in certain populations.

Common questions about Celocurine (FAQ)

Q: What are the brand names for the drug Suxamethonium Chloride?

A: The active ingredient in Celocurine is Suxamethonium Chloride, which is also known by its nonproprietary name, Succinylcholine Chloride. Regulatory documentation indicates this medicine is also sold under other brand names, which can include Quelicin and Anectine.

Q: Can Celocurine be safely used in pregnant or breastfeeding women?

A: Official product information advises caution for use during both pregnancy and lactation. Official information notes that reduced levels of the enzyme that breaks down the medicine (plasma cholinesterase) may prolong the drug's effect during pregnancy. Additionally, official information advises caution for use in nursing mothers because it is not known whether the drug passes into human milk.

Q: What should be done if an overdose of Celocurine is suspected?

A: If an overdose occurs, regulatory information states that the main effect is a prolonged period of muscle paralysis and difficulty breathing. The official guidance on overdose states that clinical management involves providing support for breathing and heart function until the drug's effects resolve.

Q: What is the typical dose of Celocurine for an adult?

A: The dosage of Celocurine is highly specialized and is strictly determined by a clinician based on individual need and body weight. Regulatory labels define limits for the total amount of medication that may be administered over a specific time period. The official prescribing information confirms that for procedures like intubation, the typical dose is based on the patient's weight.

How to Store and Dispose of Celocurine (Suxamethonium Chloride)

The storage and disposal of Suxamethonium Chloride solution for injection are defined by official regulatory requirements to maintain product integrity and safety.

---

Mandatory Storage Conditions

The unopened medicinal product must be stored under refrigeration, with the temperature maintained strictly between 2 C and 8 C. It is mandatory to not freeze the solution. The product must be kept in its original container to ensure protection from light.

Handling and Disposal Rules

As with all medicines, Celocurine must be stored out of the sight and reach of children.

Once the solution has been opened or diluted, it is intended for immediate use, and any remainder must be discarded. Disposal of unused medicinal product or waste material must be carried out in accordance with local pharmaceutical waste requirements.